1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Encouraging Signs For Galapagos In CLL, But “Point-Of-Care CAR-T” Is Biggest Challenge

 
• By Andrew McConaghie

Early data suggests its CAR-T could crack the tough challenge in CLL – but developing an automated CAR-T production unit for local hospitals is likely to be Galapagos’s greatest test.

Cocoon
Galapagos is developing its point-of-care 'Cocoon' manufacturing system to bring CAR-T to many more patients globally.

In a crowded field, Galapagos needs to find a niche where its point-of-care CAR-T concept can shine – and believes chronic lymphocytic leukemia could be it.

The company hosted a key opinion leader webinar at the American Society of Hematology on 10 December to highlight updated results from

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.